First Time Loading...
G

Guilin Sanjin Pharmaceutical Co Ltd
SZSE:002275

Watchlist Manager
Guilin Sanjin Pharmaceutical Co Ltd
SZSE:002275
Watchlist
Price: 13.96 CNY -1.06% Market Closed
Updated: May 29, 2024
Section:
 

Relative Value

The Relative Value of one Guilin Sanjin Pharmaceutical Co Ltd stock under the Base Case scenario is 12.16 CNY. Compared to the current market price of 13.96 CNY, Guilin Sanjin Pharmaceutical Co Ltd is Overvalued by 13%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
12.16 CNY
Overvaluation 13%
Relative Value
Price
G
Worst Case
Base Case
Best Case

Valuation Multiples

4.2
P/S
P/S
Price to Sales
4.2
vs History
52
vs Industry
30
Median 3Y
4.2
Median 5Y
4.3
Industry
2.4
Forward
3.1
More Details
23.3
P/E
P/E
Price to Earnings
23.3
vs History
33
vs Industry
21
Median 3Y
23.3
Median 5Y
22
Industry
22.8
Forward
15.4
More Details
15.8
P/OCF
P/OCF
Price to OCF
15.8
vs History
46
vs Industry
27
Median 3Y
17.7
Median 5Y
15.4
Industry
17
More Details
25.3
P/FCFE
P/FCFE
Price to FCFE
25.3
vs History
22
vs Industry
19
Median 3Y
22.6
Median 5Y
19.4
Industry
23.2
More Details
2.9
P/B
P/B
Price to Book Value
2.9
vs History
23
vs Industry
28
Median 3Y
2.8
Median 5Y
2.5
Industry
2.1
More Details
3.9
EV/S
EV/S
Enterprise Value to Sales
3.9
vs History
31
vs Industry
31
Median 3Y
3.7
Median 5Y
3.7
Industry
2.6
Forward
2.8
More Details
5.4
EV/GP
EV/GP
Enterprise Value to Gross Profit
5.4
vs History
26
vs Industry
40
Median 3Y
5.2
Median 5Y
5.1
Industry
5.1
More Details
18.7
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
18.7
vs History
17
vs Industry
20
Median 3Y
17.1
Median 5Y
15.8
Industry
13.5
Forward
9.4
More Details
18.7
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
18.7
vs History
17
vs Industry
24
Median 3Y
17.1
Median 5Y
15.8
Industry
16.9
More Details
14.4
EV/OCF
EV/OCF
Enterprise Value to OCF
14.4
vs History
41
vs Industry
30
Median 3Y
15.7
Median 5Y
13.8
Industry
15.8
More Details
16.7
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
16.7
vs History
58
vs Industry
23
Median 3Y
20.2
Median 5Y
17.7
Industry
17.7
More Details
2.9
EV/IC
EV/IC
Enterprise Value to IC
2.9
vs History
47
vs Industry
28
Median 3Y
2.9
Median 5Y
2.9
Industry
1.9
More Details

Multiples Across Competitors

Competitors Multiples
Guilin Sanjin Pharmaceutical Co Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CN
Guilin Sanjin Pharmaceutical Co Ltd
SZSE:002275
8.2B CNY 4.2 23.3 18.7 18.7
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
767.8B USD 21.4 125.1 61.2 69.6
DK
Novo Nordisk A/S
CSE:NOVO B
4.1T DKK 16.7 45.7 34.1 37.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
347.5B USD 4.1 9 11.1 14.5
US
Merck & Co Inc
NYSE:MRK
319.3B USD 5.2 138.5 34.6 56.4
UK
AstraZeneca PLC
LSE:AZN
186.5B GBP 5 37.6 174.5 278.3
CH
Roche Holding AG
SIX:ROG
182.4B CHF 3.1 15.9 9 10.7
CH
Novartis AG
SIX:NOVN
178.3B CHF 3.3 11.1 8.5 12.4
US
Pfizer Inc
NYSE:PFE
160.4B USD 2.9 -519 12.6 20.4
P/E Multiple
Earnings Growth
CN
G
Guilin Sanjin Pharmaceutical Co Ltd
SZSE:002275
Average P/E: 50.8
23.3
N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A
US
Eli Lilly and Co
NYSE:LLY
125.1
364%
DK
Novo Nordisk A/S
CSE:NOVO B
45.7
83%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A
US
Johnson & Johnson
NYSE:JNJ
9
-21%
US
Merck & Co Inc
NYSE:MRK
138.5
7 598%
UK
AstraZeneca PLC
LSE:AZN
37.6
175%
CH
Roche Holding AG
SIX:ROG
15.9
28%
CH
Novartis AG
SIX:NOVN
11.1
17%
US
Pfizer Inc
NYSE:PFE
Negative Multiple: -519
683%

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 141,700+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.